Ligand Pharmaceuticals LGND Contract revenue and income — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's contract revenue and income — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's contract revenue and income — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported contract revenue and income — total revenues and income of $110K in Q1 2026.
- How has Ligand Pharmaceuticals's contract revenue and income — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's contract revenue and income — total revenues and income decreased by 97.5% year-over-year, from $4.38M to $110K.
- What does contract revenue and income — total revenues and income mean?
- This metric represents the aggregate financial inflows generated from contract-based arrangements, including license fees, milestone payments, and service-related income within a specific business segment. It reflects the company's ability to monetize its intellectual property and development expertise through strategic partnerships with third-party pharmaceutical and biotechnology entities. This revenue stream is a key indicator of the commercial success and adoption of the company's underlying technology platforms.